Cargando…

Immune Checkpoint Inhibition in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Forster, Martin David, Devlin, Michael-John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123367/
https://www.ncbi.nlm.nih.gov/pubmed/30211111
http://dx.doi.org/10.3389/fonc.2018.00310
_version_ 1783352824584732672
author Forster, Martin David
Devlin, Michael-John
author_facet Forster, Martin David
Devlin, Michael-John
author_sort Forster, Martin David
collection PubMed
description Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As understanding of the underlying cancer biology and the complex interactions within the tumor microenvironment improves, there is gathering interest in and evidence for the role of immunomodulating agents in the management of HNSCC. Immune checkpoint inhibitors, which aim to hinder the inhibitory interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, have demonstrated durable improvements in patient outcomes in advanced / metastatic HNSCC, with both pembrolizumab and nivolumab being granted FDA approval in 2016. There are numerous ongoing clinical trials exploring the role of checkpoint inhibitors both as single agents and in combination, administered with established treatment modalities such as chemotherapy and radiotherapy, as well as alongside other novel immune modulators. These trials are not limited to advanced / metastatic HNSCC, but also to the neo-adjuvant or adjuvant settings. As studies complete and more results become available, the role immunotherapy agents will have within the treatment strategies for HNSCC may change, with increasing biomarker selection resulting in personalized therapy aiming to further improve patient outcomes.
format Online
Article
Text
id pubmed-6123367
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61233672018-09-12 Immune Checkpoint Inhibition in Head and Neck Cancer Forster, Martin David Devlin, Michael-John Front Oncol Immunology Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As understanding of the underlying cancer biology and the complex interactions within the tumor microenvironment improves, there is gathering interest in and evidence for the role of immunomodulating agents in the management of HNSCC. Immune checkpoint inhibitors, which aim to hinder the inhibitory interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, have demonstrated durable improvements in patient outcomes in advanced / metastatic HNSCC, with both pembrolizumab and nivolumab being granted FDA approval in 2016. There are numerous ongoing clinical trials exploring the role of checkpoint inhibitors both as single agents and in combination, administered with established treatment modalities such as chemotherapy and radiotherapy, as well as alongside other novel immune modulators. These trials are not limited to advanced / metastatic HNSCC, but also to the neo-adjuvant or adjuvant settings. As studies complete and more results become available, the role immunotherapy agents will have within the treatment strategies for HNSCC may change, with increasing biomarker selection resulting in personalized therapy aiming to further improve patient outcomes. Frontiers Media S.A. 2018-08-29 /pmc/articles/PMC6123367/ /pubmed/30211111 http://dx.doi.org/10.3389/fonc.2018.00310 Text en Copyright © 2018 Forster and Devlin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Forster, Martin David
Devlin, Michael-John
Immune Checkpoint Inhibition in Head and Neck Cancer
title Immune Checkpoint Inhibition in Head and Neck Cancer
title_full Immune Checkpoint Inhibition in Head and Neck Cancer
title_fullStr Immune Checkpoint Inhibition in Head and Neck Cancer
title_full_unstemmed Immune Checkpoint Inhibition in Head and Neck Cancer
title_short Immune Checkpoint Inhibition in Head and Neck Cancer
title_sort immune checkpoint inhibition in head and neck cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123367/
https://www.ncbi.nlm.nih.gov/pubmed/30211111
http://dx.doi.org/10.3389/fonc.2018.00310
work_keys_str_mv AT forstermartindavid immunecheckpointinhibitioninheadandneckcancer
AT devlinmichaeljohn immunecheckpointinhibitioninheadandneckcancer